PharmaVentures expands their Pricing and Market Access team with the appointment of new Director, Angela Acosta
PharmaVentures is pleased to announce the appointment of Angela Acosta as the new Director of Pricing and Market Access.
Soren Demin joins PharmaVentures as Head of M&A
PharmaVentures is pleased to announce the appointment of Soren Demin as Managing Director and Head of M&A.
PharmaVentures acts as the exclusive M&A advisor on the successful sale of Phasefocus to Bruker
London, UK, 20 September 2023: PharmaVentures is pleased to announce it recently acted as exclusive M&A advisor on the sale of a European pharmaceutical services operation to a US corporation.
PharmaVentures acts as exclusive M&A advisor on the successful sale of a European pharmaceutical services operation to a US Corporation
London, UK, 20 September 2023: PharmaVentures is pleased to announce it recently acted as exclusive M&A advisor on the sale of a European pharmaceutical services operation to a US corporation.
PharmaVentures advises Douglas Pharmaceuticals on its licensing deal with Daré Bioscience
London, UK, 6 September 2023: PharmaVentures is pleased to announce that it acted as the exclusive advisor to Douglas Pharmaceuticals on its U.S. license agreement with Daré Bioscience, Inc. (NASDAQ: DARE) to develop and commercialise R-131-2, a novel
PharmaVentures supports GeneCode’s successful record-breaking submission to European Innovation Council Accelerator
PharmaVentures congratulates GeneCode on their successful application to the European Innovation Council (EIC) Accelerator, securing a groundbreaking funding package of €16 million.
PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs
London, UK, 29 March 2023: PharmaVentures announces its new office in Korea as part of its continued strategic expansion. Headquartered in London, UK, PharmaVentures has been assisting Korean biopharma companies for more than 5 years on various transaction and...
PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)
London based deal experts are the exclusive advisors for this and the ongoing partnering efforts for WM-A1-3389. London, UK, 08 February 2023: PharmaVentures is pleased to announce that it acted as exclusive advisor for Wellmarker Bio Co., Ltd (WMBIO) on its...
PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
London-based deal experts are the advisors for this collaboration and the ongoing partnering efforts for IntoCell's platform technologies and its lead programme, B7-H3 ADC. London, UK, 05 January 2023: PharmaVentures is pleased to announce that it acted as exclusive...
PharmaVentures’ new Vice President recruited to lead Pricing and Market Access practice
Ralph Hughes joins the corporate advisory team to support clients in bringing their products to market London, UK, 27 September 2022: PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market...
PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies
London, UK, 24 March, 2022 PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2...
PharmaVentures moves HQ to London to support its continued growth strategy
London, UK, 10 February 2022 PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and...
PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry
Oxford, UK, 18 November 2021 PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian...
PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio
Oxford, UK, 15 October 2021 PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio. This follows the recent announcement that IntoCell has established a research collaboration partnership...
PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar
Oxford, UK, 15 July 2021 PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar. This follows the announcement that Cellectar and Intocell have expanded their collaboration using...
PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM
Oxford, UK, 29 June 2021 PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd. Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our...
PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
Oxford, UK, 03 March 2021 PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH. ERA Consulting is a leading strategic product development and regulatory consulting group serving the...
PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor
Oxford, UK, 24th November 2020 PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4. GPCR has signed an exclusive agreement with TaiGen Biotechnology...